respiratori
virus
rv
lead
caus
infectionrel
morbid
mortal
patient
undergo
treatment
cancer
analysi
compar
durat
rv
shed
detect
cultur
pcr
among
patient
highrisk
oncolog
set
adult
patient
haematolog
malign
andor
stem
cell
transplant
paediatr
oncolog
patient
determin
risk
factor
extend
shed
rv
infect
due
influenza
viru
parainfluenza
viru
piv
human
metapneumoviru
hmpv
respiratori
syncyti
viru
rsv
two
studi
period
pcrbase
test
review
retrospect
data
collect
patient
retest
viral
clearanc
carri
within
day
recent
test
studi
period
patient
diagnos
rv
infect
pcr
cultur
median
rang
durat
shed
day
cultur
pcr
respect
followsinfluenza
viru
day
day
versu
day
day
p
rsv
day
day
versu
day
day
p
piv
day
day
versu
day
day
p
hmpv
day
day
versu
day
day
p
multivari
analysi
age
underli
diseas
transplant
independ
associ
extend
shed
regardless
test
method
highrisk
oncolog
set
respiratori
ill
due
rsv
piv
viru
detect
pcr
longer
period
time
cultur
extend
shed
observ
clinic
microbiolog
infect
respiratori
virus
rv
import
caus
hospit
death
longterm
morbid
patient
undergo
treatment
haematolog
malign
prevent
persontoperson
transmiss
rv
utmost
import
infect
control
programm
highrisk
set
rapid
diagnosi
prompt
isol
rvinfect
person
facilit
widespread
avail
nucleic
acid
amplif
test
although
molecularbas
rv
detect
sever
advantag
includ
higher
sensit
improv
turnaround
time
protract
shed
frequent
encount
sequenti
viru
detect
extend
durat
make
difficult
ascertain
rvinfect
person
longer
contagi
immunosuppress
patient
may
shed
higher
amount
virus
greater
length
time
first
becom
infect
rv
healthi
patient
infect
viru
howev
littl
known
durat
shed
detect
convent
versu
molecular
test
method
popul
biolog
signific
persist
detect
viral
gene
without
concomit
symptom
person
recuper
rv
infect
complet
understood
although
asymptomat
shed
parainfluenza
viru
piv
respiratori
syncyti
viru
rsv
associ
perpetu
nosocomi
outbreak
current
infect
control
approach
toward
longterm
shed
rv
formal
address
healthcar
infect
control
practic
advisori
committe
guidelin
american
societi
blood
marrow
transplant
guidelin
vari
approach
use
across
oncolog
transplant
centr
includ
symptombas
polici
andor
test
cure
guid
discontinu
droplet
precaut
aim
analysi
compar
durat
virusspecif
shed
detect
cultur
pcr
among
highrisk
patient
includ
haematolog
malign
leukaemia
lymphoma
stem
cell
transplant
sct
recipi
determin
risk
factor
extend
shed
among
highrisk
patient
inform
could
use
guid
isol
retest
polici
rv
newer
molecular
base
test
memori
sloan
ketter
cancer
center
mskcc
tertiari
care
cancer
centr
new
york
citi
annual
admiss
patientday
base
censu
data
patient
diagnos
rv
place
droplet
precaut
test
cure
requir
discontinu
droplet
precaut
influenza
viru
piv
rsv
human
metapneumoviru
hmpv
retest
recommend
sooner
day
initi
test
retrospect
review
rv
test
result
among
highrisk
patient
two
distinct
studi
phase
purpos
studi
high
risk
includ
paediatr
oncolog
patient
adult
patient
haematolog
malign
sct
leukaemia
lymphoma
etc
two
studi
phase
repres
transit
convent
molecularbas
detect
rv
mskcc
clinic
microbiolog
laboratori
test
rv
perform
nasopharyng
swab
januari
septemb
combin
direct
fluoresc
antibodi
viral
culturebas
diagnost
approach
use
sampl
period
test
direct
fluoresc
antibodi
cultur
cultureposit
sampl
label
case
molecular
detect
rv
see
laboratori
method
implement
septemb
elig
case
diagnos
septemb
april
pcrbase
test
review
purpos
comparison
two
studi
period
refer
cultur
pcr
cohort
respect
patient
includ
test
posit
influenza
viru
influenza
b
viru
piv
hmpv
andor
rsv
first
retest
viral
clearanc
within
day
last
posit
test
subsequ
test
record
includ
neg
test
viru
interest
extend
shed
defin
viral
detect
beyond
day
patient
multipl
episod
due
distinct
virus
studi
period
first
episod
includ
analysi
addit
rv
test
result
patient
symptom
time
retest
also
review
pcr
cohort
specif
electron
medic
record
review
determin
presenc
absenc
fever
cough
rhinorrhoea
sinu
congest
lower
respiratori
infect
defin
presenc
new
radiograph
abnorm
chest
imag
absolut
lymphocyt
count
patient
time
reswab
mskcc
nasopharyng
swab
use
detect
rv
viral
cultur
perform
describ
earlier
studi
virus
detect
combin
direct
fluoresc
antibodi
viral
cultur
includ
follow
nine
virus
influenza
viru
influenza
b
viru
piv
rsv
adenoviru
hmpv
rhinovirus
turnaround
time
receipt
nasopharyng
swab
laboratori
final
result
vari
day
pcr
perform
fda
clear
film
array
respiratori
panel
autom
multiplex
system
detect
respiratori
pathogensadenoviru
bocaviru
coronaviru
type
influenza
viru
includ
subtyp
determin
influenza
b
viru
mpv
piv
type
rsv
rhinoviru
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
biofir
diagnost
inc
salt
lake
citi
ut
usa
turnaround
time
receipt
nasopharyng
swab
laboratori
final
result
vari
h
categor
variabl
compar
use
chisquar
test
continu
variabl
normal
distribut
therefor
compar
use
wilcoxonmannwhitney
rank
sum
test
time
neg
analys
conduct
use
kaplanmei
method
logrank
test
risk
factor
longterm
shed
defin
test
posit
week
initi
diagnosi
evalu
multivari
logist
regress
model
test
via
pcr
versu
cultur
age
gender
underli
cancer
type
sct
statu
consid
sinc
retest
systemat
perform
determin
associ
risk
factor
test
frequenc
model
built
addit
adjust
test
frequenc
defin
mean
number
day
test
pvalu
consid
statist
signific
statist
analys
perform
use
sa
mskcc
institut
review
board
grant
hipaa
waiver
conduct
studi
januari
april
rv
episod
occur
studi
popul
retest
perform
day
recent
test
among
test
neg
upon
retest
occur
within
day
initi
diagnosi
episod
occur
episod
detect
cultur
patient
episod
detect
pcr
patient
demograph
clinic
characterist
patient
two
studi
cohort
cultur
pcr
includ
analysi
shown
tabl
rv
episod
detect
cultur
episod
detect
cultur
occur
patient
age
rang
month
year
mean
year
seventyseven
patient
paediatr
oncolog
servic
allogen
sct
recipi
leukaemia
five
lymphoma
neuroblastoma
sarcoma
nine
cancer
patient
adult
haematolog
malign
allogen
sct
recipi
autolog
sct
recipi
undergo
treatment
leukaemia
undergo
treatment
lymphoma
seven
undergo
treatment
multipl
myeloma
rv
episod
detect
pcr
pcrdetect
episod
includ
uniqu
patient
age
rang
month
year
mean
year
patient
paediatr
oncolog
servic
allogen
sct
recipi
leukaemia
seven
lymphoma
neuroblastoma
sarcoma
cancer
patient
adult
haematolog
malign
allogen
autolog
sct
recipi
undergo
treatment
leukaemia
undergo
treatment
lymphoma
undergo
treatment
multipl
myeloma
test
frequenc
per
studi
protocol
patient
retest
five
day
initi
test
includ
median
time
first
retest
day
first
retest
occur
median
day
cultureera
patient
day
pcr
patient
p
mean
retest
frequenc
rang
day
median
day
major
patient
test
neg
first
retest
median
test
frequenc
vari
patient
group
patient
test
pcr
test
slightli
less
often
test
cultur
versu
day
p
paediatr
patient
age
group
test
often
median
day
follow
age
year
day
age
year
day
p
bone
marrow
transplant
patient
test
less
often
patient
versu
day
mean
test
frequenc
pathogen
also
significantli
differ
first
rv
episod
among
patient
median
durat
shed
rang
day
cultur
pcr
respect
followsinfluenza
day
versu
day
day
p
rsv
day
versu
day
fig
show
comparison
shed
time
cultur
pcr
virus
overal
median
centil
shed
durat
rsv
piv
significantli
longer
pcr
compar
culturebas
viral
detect
fig
pcr
known
sensit
cultur
includ
model
patient
test
use
pcr
higher
likelihood
viral
detect
beyond
day
initi
diagnosi
model
adjust
retest
interv
ci
p
tabl
also
examin
risk
factor
extend
shed
defin
viral
detect
last
day
day
median
time
neg
cohort
allogen
sct
signific
risk
factor
shed
last
longer
day
model
adjust
test
frequenc
tabl
none
four
viru
group
longer
shed
time
observ
pcr
cohort
review
data
symptom
time
retest
data
avail
retest
patient
signific
associ
seen
exist
symptom
posit
yield
repeat
test
patient
cough
rhinorrhoea
lower
respiratori
infect
absolut
lymphocyt
count
time
retest
like
still
shed
viru
howev
symptom
suffici
reliabl
marker
assess
presenc
detect
viru
supplementari
tabl
appendix
fourteen
patient
shed
last
day
exclud
primari
analysi
detect
viru
day
median
day
test
pcr
among
outlier
test
pcr
sct
recipi
infect
type
follow
five
influenza
viru
four
piv
two
rsv
two
hmpv
diagnosi
rv
infect
among
immunosuppress
patient
great
import
health
risk
infect
individu
potenti
onward
transmiss
cultur
molecularbas
test
pcr
two
wide
avail
high
sensit
test
method
rv
current
use
healthcar
provid
care
immunocompromis
patient
although
test
method
affect
length
shed
use
pcr
versu
cultur
test
may
affect
detect
extend
shed
though
pcr
faster
sensit
diagnost
tool
cultur
differenti
activ
replic
nonviabl
organ
moreov
viral
cultur
success
depend
mani
factor
includ
sampl
collect
storag
condit
viru
type
viral
load
cell
line
although
posit
viru
cultur
may
indic
viabl
viru
neg
result
necessarili
indic
absenc
viabl
viru
henc
test
cure
isol
polici
rvposit
patient
remain
unclear
find
indic
pcr
detect
significantli
longer
durat
viral
shed
cultur
immunosuppress
patient
longterm
shed
last
day
observ
minor
patient
pattern
describ
studi
compar
report
shed
durat
use
molecular
test
among
highrisk
patient
notabl
sct
solid
organ
transplant
recipi
examin
viru
type
extend
shed
pcrbase
test
observ
frequent
paramyxovirus
piv
rsv
find
particular
relev
popul
asymptomat
shedder
suspect
sourc
nosocomi
outbreak
caus
piv
rsv
observ
data
recent
outbreak
highrisk
set
suggest
extens
contact
droplet
precaut
entir
durat
shed
detect
pcr
essenti
strategi
outbreak
prevent
control
two
virus
interestingli
shed
pattern
influenza
viru
similar
among
cultur
pcr
cohort
may
influenc
earli
use
antivir
agent
pcr
test
oseltamivir
wide
use
studi
period
regardless
time
diagnosi
symptom
onset
current
standard
care
manag
influenza
institut
pcr
enabl
earli
diagnosi
treatment
compar
viral
cultur
plausibl
earli
initi
antivir
reduc
period
contagi
data
support
notion
although
valid
prospect
design
studi
need
find
also
suggest
transit
convent
molecularbas
detect
method
rv
result
signific
increas
isol
day
oncolog
transplant
centr
use
test
cure
approach
discontinu
precaut
howev
high
neg
predict
valu
pcr
compar
viral
cultur
allow
earlier
discontinu
isol
symptomat
person
rv
infect
experi
excess
isol
day
requir
shedder
offset
reduct
isol
day
symptomat
patient
suspect
rv
infect
would
remain
isol
convent
test
method
result
final
altern
approach
determin
rv
isol
polici
appli
viral
load
cutoff
threshold
cycl
valu
correl
cultur
posit
proxi
discontinu
droplet
precaut
akin
use
smear
posit
tuberculosi
current
avail
molecular
platform
capabl
perform
reliabl
quantit
assess
variabl
sampl
techniqu
potenti
drawback
strategi
analysi
patient
symptom
time
followup
pcr
test
demonstr
symptombas
assess
viral
shed
complet
reliabl
use
exclus
criterion
infect
resolut
highrisk
patient
studi
report
similar
find
report
sever
limit
patient
systemat
retest
preset
nonvari
interv
howev
adjust
test
frequenc
multivari
model
exclud
small
proport
outlier
viral
detect
exceed
day
assess
shed
clinic
microbiolog
infect
volum
number
april
common
respiratori
virus
includ
rhinoviru
coronavirus
adenoviruscomparison
cultur
possibl
shed
due
virus
previous
character
welldesign
prospect
studi
moreov
viral
genom
sequenc
data
could
confirm
subsequ
posit
result
detect
viru
initi
test
avail
final
made
comparison
across
season
variabl
circul
viral
strain
may
affect
shed
pattern
although
plausibl
notion
disproven
recent
studi
compar
shed
pattern
season
influenza
strain
retrospect
analysi
rv
infect
among
immunosuppress
patient
indic
durat
viral
shed
detect
pcr
significantli
longer
cultur
rsv
piv
influenza
viru
hmpv
overal
viral
detect
beyond
day
found
occasion
patient
shed
viru
longer
daysth
major
sever
immunosuppress
allogen
sct
recipi
although
found
correl
symptom
time
retest
respect
test
result
data
suggest
symptombas
strategi
may
complet
reliabl
tool
infer
transmiss
activ
viral
replic
immunosuppress
patient
taken
togeth
find
studi
provid
comparison
shed
pattern
observ
culturebas
pcrbase
method
rv
use
inform
infect
control
practic
oncolog
centr
transit
convent
sensit
molecularbas
approach
diagnosi
rv
made
data
transmiss
avail
extend
droplet
precaut
durat
rv
shed
practic
ration
approach
highrisk
set
